Spyre Therapeutics Inc.

NASDAQ: SYRE · Real-Time Price · USD
16.93
0.07 (0.42%)
At close: Aug 15, 2025, 3:59 PM
16.95
0.12%
After-hours: Aug 15, 2025, 07:36 PM EDT

Spyre Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a n/a n/a n/a n/a n/a n/a 688K 198K 168K 174K 625K 1.36M 3.64M 1.4M 13.7M n/a
Cost of Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Gross Profit
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Income
-41.94M -53.57M -61.25M -55.39M -44.15M -47.77M -45.91M -18.34M -159.25M -18.81M -19.16M -18.75M -22.42M -24.44M -20.44M -20.29M -6.71M -18.21M
Interest Income
5.87M 6.49M 5.78M 5.18M 5.92M 4.43M 4.13M 1.25M 350K 420K 410K 288K 104K 35K 34K 36K 19K 22K
Pretax Income
-36.72M -44.79M -56.3M -69.01M -38.84M -43.83M -63.18M -40.1M -217.07M -18.46M -18.78M -18.44M -22.31M -24.44M -20.42M -20.28M -6.74M -18.22M
Net Income
-36.72M -44.77M -56.3M -69.03M -38.84M -43.86M -63.18M -40.11M -217.08M -18.42M -18.82M -18.23M -22.32M -24.44M -20.45M -20.31M -6.83M -18.22M
Selling & General & Admin
11.79M 11.94M 10.77M 10.65M 11.51M 12.85M 14.07M 8.58M 12.06M 5.23M 5.08M 6.95M 7.67M 8.82M 7.3M 6.84M 6.82M 6.35M
Research & Development
40.15M 41.62M 50.48M 44.74M 32.64M 34.93M 33.68M 24.66M 17.39M 13.78M 14.25M 11.98M 15.37M 16.98M 16.78M 14.85M 13.58M 11.86M
Other Expenses
-10M n/a n/a n/a n/a n/a -1.84M -14.91M 130.49M n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
41.94M 53.57M 61.25M 55.39M 44.15M 47.77M 45.91M 18.34M 159.93M 19M 19.33M 18.93M 23.05M 25.8M 24.09M 21.69M 20.4M 18.21M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
41.94M 53.57M 61.25M 55.39M 44.15M 47.77M 45.91M 18.34M 159.93M 19M 19.33M 18.93M 23.05M 25.8M 24.09M 21.69M 20.4M 18.21M
Income Tax Expense
n/a -15K 1K 18K n/a 32K n/a 3K 7K -36K 38K -209K 9K n/a 23K 26K 92K n/a
Shares Outstanding (Basic)
60.7M 60.27M 47.03M 50.89M 45.32M 36.51M 6.9M 4.29M 3.82M 3.77M 2.61M 3.77M 3.29M 2.64M 1.97M 2.63M 2.63M 2.62M
Shares Outstanding (Diluted)
60.7M 60.27M 47.03M 50.89M 45.32M 36.51M 6.9M 4.29M 3.82M 3.77M 2.61M 3.77M 3.29M 2.64M 1.97M 2.63M 2.63M 2.62M
EPS (Basic)
-0.6 -0.13 -0.15 -1.36 -0.86 -1.2 -11.29 -9.34 -56.79 -4.89 -7.2 -4.84 -6.79 -9.26 -10.36 -7.72 -2.6 -6.94
EPS (Diluted)
-0.6 -0.13 -0.15 -1.36 -0.86 -1.2 -11.29 -9.34 -56.79 -4.89 -7.2 -4.84 -6.79 -9.26 -10.36 -7.72 -2.6 -6.94
EBITDA
-51.94M -53.57M -61.25M -55.39M -44.15M -47.77M -47.75M -33.24M -28.34M -18.26M -18.78M -18.25M -21.85M -24.04M -20.03M -19.88M -6.31M -17.85M
EBIT
-51.94M -53.57M -61.25M -55.39M -44.15M -47.77M -47.75M -33.24M -28.76M -18.81M -19.16M -18.75M -22.42M -24.44M -20.44M -20.29M -6.71M -18.21M
Depreciation & Amortization
n/a n/a n/a n/a n/a n/a -220K n/a 416K 548K 385K 502K 569K 403K 411K 412K 398K 355K